Australia - inglese - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - risperidone, quantity: 4 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; lactose monohydrate; sodium lauryl sulfate; pregelatinised maize starch; colloidal anhydrous silica; titanium dioxide; hypromellose; propylene glycol; purified talc; quinoline yellow aluminium lake; indigo carmine aluminium lake - rixadone is indicated for,- the treatment of schizophrenia and related psychoses.,- the short term treatment of acute mania associated with bipolar 1 disorder (see dosage and administration: bipolar mania).,- the treatment (up to 12 weeks) of psychotic symptoms, or persistent agitation or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe dementia of the alzheimer type. (see dosage and administration: behavioural disturbances in dementia).,- the treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent (see clinical trials for maintenance data).,- the treatment of behavioural disorders associated with autism in children and adolescents (see clinical trials).

Australia - inglese - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - risperidone, quantity: 2 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; sodium lauryl sulfate; colloidal anhydrous silica; lactose monohydrate; microcrystalline cellulose; magnesium stearate; titanium dioxide; hypromellose; propylene glycol; sunset yellow fcf aluminium lake; purified talc - rixadone is indicated for,- the treatment of schizophrenia and related psychoses.,- the short term treatment of acute mania associated with bipolar 1 disorder (see dosage and administration: bipolar mania).,- the treatment (up to 12 weeks) of psychotic symptoms, or persistent agitation or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe dementia of the alzheimer type. (see dosage and administration: behavioural disturbances in dementia).,- the treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent (see clinical trials for maintenance data).,- the treatment of behavioural disorders associated with autism in children and adolescents (see clinical trials).

Australia - inglese - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - finasteride, quantity: 5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; pregelatinised maize starch; microcrystalline cellulose; sodium starch glycollate type a; magnesium stearate; docusate sodium; titanium dioxide; hypromellose; indigo carmine aluminium lake; macrogol 400 - treatment of patients with symptomatic benign prostatic hyperplasia (bph) with an enlarged prostate.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - risperidone, quantity: 2 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; hypromellose; microcrystalline cellulose; propylene glycol; magnesium stearate; titanium dioxide; lactose monohydrate; sunset yellow fcf aluminium lake; sodium lauryl sulfate; purified talc; maize starch - treatment of schizophrenia and related psychoses. . short term treatment of acute mania associated with bipolar 1 disorder. . treatment of behavioural disturbances in dementia. . treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent. . treatment of behavioural disorders associated with autism in children and adolescents.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - risperidone, quantity: 4 mg - tablet, film coated - excipient ingredients: maize starch; microcrystalline cellulose; quinoline yellow aluminium lake; propylene glycol; purified talc; indigo carmine aluminium lake; colloidal anhydrous silica; lactose monohydrate; sodium lauryl sulfate; titanium dioxide; hypromellose; magnesium stearate - treatment of schizophrenia and related psychoses. . short term treatment of acute mania associated with bipolar 1 disorder. . treatment of behavioural disturbances in dementia. . treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent. . treatment of behavioural disorders associated with autism in children and adolescents.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - risperidone, quantity: 3 mg - tablet, film coated - excipient ingredients: titanium dioxide; sodium lauryl sulfate; microcrystalline cellulose; colloidal anhydrous silica; lactose monohydrate; purified talc; magnesium stearate; quinoline yellow aluminium lake; hypromellose; propylene glycol; maize starch - treatment of schizophrenia and related psychoses. . short term treatment of acute mania associated with bipolar 1 disorder. . treatment of behavioural disturbances in dementia. . treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent. . treatment of behavioural disorders associated with autism in children and adolescents.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - lercanidipine hydrochloride, quantity: 10 mg; enalapril maleate, quantity: 20 mg - tablet, film coated - excipient ingredients: lactose monohydrate; sodium bicarbonate; purified talc; quinoline yellow aluminium lake; sodium starch glycollate type a; iron oxide yellow; magnesium stearate; microcrystalline cellulose; hypromellose; titanium dioxide; povidone; macrogol 6000 - treatment of hypertension. treatment should not be initiated with these fixed dose combinations. (see dosage and administration).

Australia - inglese - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - teriflunomide, quantity: 14 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; allura red ac aluminium lake; purified water; magnesium stearate; sodium starch glycollate type a; hypromellose; purified talc; maize starch; titanium dioxide; microcrystalline cellulose; glycerol; lactose monohydrate; hyprolose; indigo carmine aluminium lake; brilliant blue fcf aluminium lake - for the treatment of patients with relapsing forms of multiple sclerosis to reduce the frequency of clinical relapses and to delay the progression of physical disability.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - lacosamide, quantity: 50 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; crospovidone; magnesium stearate; hyprolose; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black; lecithin; indigo carmine aluminium lake - lacosamide lupin tablets are indicated as: ? monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. ? add-on therapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older. ? add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - lacosamide, quantity: 200 mg - tablet, film coated - excipient ingredients: hyprolose; microcrystalline cellulose; magnesium stearate; crospovidone; colloidal anhydrous silica; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350; lecithin; indigo carmine aluminium lake - lacosamide lupin tablets are indicated as: ? monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. ? add-on therapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older. ? add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older.